Waters (WAT) Q2 FY25 earnings call

Waters Corporation delivered strong Q2 FY25 results, with sales and non-GAAP EPS exceeding guidance, driven by robust commercial execution and new product traction. The company raised its full-year outlook, reflecting confidence in its core business momentum and strategic expansion into high-growth adjacencies. Management also provided extensive details on the strategic rationale and synergy potential of the pending acquisition of BD's Biosciences and Diagnostic Solutions business, emphasizing operational improvements and cross-selling opportunities.